Splicing factor levels predict patient prognosis and indicate drug efficacy
|
Categories |
Oncology/Cancer, RNA/Protein/Diagnosis, Biomarkers |
|
Development Stage |
Proof of concept in vitro and in small animals |
|
Patent Status |
Patent filed in the United States |
|
Market |
Cancer testing is currently one of the most important growth opportunities diagnostics segment. The worldwide market for in vitro cancer diagnosis is estimated in few billions. |
Highlights
-
Detection of the levels of specific splicing factors used to indicate presence of cancer and cancer outcome.
-
Successfully demonstrated ability to predict the survival time of patients with brain tumors and to detect the metastatic stages of breast cancer
-
Down-regulation of specific splicing factors inhibits glioblastoma development and metastasis of breast cell into the lungs in mouse xenograft models
-
Splicing factor levels are better prognostic markers than markers currently in use.
-
Highly sensitive diagnostic tool
-
New treatment approach
Our Innovation
Novel approach to diagnosing cancer and a patient's sensitivity to specific drugs using the levels in the body of certain splicing factors as markers; local down-regulation of splicing factors by Antisense RNA oligos for the treatment of glioblastoma and metastatic breast cancer
Key Features
-
Accurate prediction of tumor stage and cancer severity
-
More Accurate diagnosis for efficient treatment to prevent suffering of cancer patients
-
New Efficient treatment for glioblastoma and metastatic breast cancer
Development Milestones
Seeking funding for ongoing research, further animal trials, and accumulation of patient data
The Opportunity
Applications in cancer diagnosis and a new treatment for glioblastoma and metastatic breast cancer
1586128900.png)